Core Viewpoint - The article emphasizes that the new "new three items" for China's economy are robotics, artificial intelligence (AI), and innovative pharmaceuticals, which are now driving high-quality economic growth, surpassing traditional sectors like finance and real estate [1][2]. Group 1: Robotics - The robotics sector, particularly humanoid robots, is seen as the next potential world-changing technology after computers, smartphones, and electric vehicles. Leading companies like Huichuan Technology have a market capitalization exceeding 200 billion, with some stocks experiencing significant price increases [2]. - China is making rapid progress in robotics, moving from "catching up" to "leading" on a global scale, with a complete industrial chain and the largest market, although high-end components still rely on imports [2][3]. Group 2: Artificial Intelligence - The AI sector has several companies with market capitalizations over 100 billion, focusing on AI computing chips and infrastructure. Companies like Cambricon and Industrial Fulian are experiencing explosive growth in orders and performance [2]. - China is competitive in application-level AI, particularly in computer vision and speech recognition, but still lags in foundational chips and ecosystem frameworks [3]. Group 3: Innovative Pharmaceuticals - The innovative pharmaceutical sector is witnessing significant growth, with companies like Hengrui Medicine nearing a market cap of 500 billion. The business model is shifting from "burning money" to "making money," gaining global market recognition [2]. - China's innovative drugs are moving from "following" to "keeping pace," with explosive growth in overseas transactions, although challenges remain in target discovery and basic research translation [3]. Group 4: Advantages and Challenges - China's advantages include a large-scale market providing scenario dividends, strong engineering and industrialization capabilities, and a continuously improving policy environment. However, there are risks of being "choked" if key segments are controlled by external entities [3]. - The article suggests that policy improvements are needed to create an open data ecosystem, optimize review processes, and increase investment in foundational research [4].

Core Viewpoint - The National Drug Centralized Procurement Office has announced the new centralized procurement document, emphasizing principles of clinical stability, quality assurance, prevention of collusion, and reduction of competition pressure in the pharmaceutical industry [1][3]. Summary by Sections Centralized Procurement Announcement - The announcement requires participating drugs to obtain valid domestic registration by September 28 and complete information submission on the National Medical Insurance Service Platform, with the bidding ceremony scheduled for October 21, 2025 [1]. Changes in Procurement Rules - The new procurement rules introduce a "benchmark price" for the same drug category, set at 50% of the average unit comparable price of validly declared companies and the higher value of the lowest unit comparable price. Companies can qualify for selection if their bid is below 1.8 times the benchmark price, a shift from the previous model that focused solely on the lowest price [3]. Participation and Reporting - A total of 46,359 medical institutions participated in the reporting, with 77% reporting by brand name and 23% by generic name. The drug list remains unchanged with 55 varieties, but mainstream specifications and prices have been noted [3]. Sodium Bicarbonate Injection Reporting - The total reported quantity of sodium bicarbonate injection across 31 provinces reached 71.5665 million units, with unspecified brands accounting for 47.45% of the total [5][9]. Manufacturer Performance - Among the specified brands, six manufacturers reported over 1 million units, with Shijiazhuang Fourth Pharmaceutical Company leading at 9.6542 million units, followed by Hebei Tiancai Pharmaceutical Co., Ltd. at 5.6166 million units [7][9]. Regional Preferences - Regional preferences for manufacturers are evident, with Yunnan showing a strong preference for Hebei Tiancai Pharmaceutical, while Shijiazhuang Fourth Pharmaceutical has a balanced national coverage [9][10]. Market Dynamics Ahead of Bidding - As the bidding date approaches, the market dynamics for sodium bicarbonate injection are expected to shift, influenced by brand preferences and the flow of unspecified brands, with companies that possess capacity, quality, and clinical recognition likely to emerge as winners in this round of procurement [10].

Core Viewpoint - The article provides insights into the latest perspectives and recommendations for the pharmaceutical sector, emphasizing the importance of historical context in analyzing the industry and individual stocks [4]. Group 1: Pharmaceutical Sector Insights - The research team at Guotai Junan Securities specializes in analyzing the global pharmaceutical industry over 40 years and the Chinese pharmaceutical industry over 20 years, focusing on a comprehensive view of industry development to identify investment opportunities [4]. - Key discussions are scheduled for various segments of the pharmaceutical industry, including medical devices, innovative drugs, and CXO & upstream sectors, with prominent analysts leading these discussions [5][6][7]. Group 2: Upcoming Events and Recommendations - A series of conference calls are planned from September 22 to September 26, covering different aspects of the pharmaceutical sector, with notable analysts presenting their insights and recommendations [5][6][7]. - The focus will be on recent key recommendations and deep dives into specific stocks, highlighting the ongoing analysis and updates in the pharmaceutical landscape [7].

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to return to A-share market after successfully passing the listing review by the Shanghai Stock Exchange, marking its A+H listing strategy [1] Group 1: Company Overview - Baiaosaitu, established in 2009, is a preclinical CRO and biotechnology company that provides innovative model animals and preclinical drug development services based on its proprietary gene editing technology [1] - The company has developed a comprehensive platform that includes gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Achievements - As of the reporting period, Baiaosaitu has completed over 5,100 customized gene editing projects and developed more than 3,500 types of RenMice and other gene-edited animals and cell line models [2] - The company has established partnerships with numerous renowned biotech and pharmaceutical companies for antibody drug discovery, leveraging its RenMice platform and "thousands of mice, ten thousand antibodies" approach [2] Group 3: Financial Performance - From 2022 to 2024, Baiaosaitu's revenue is projected to be 534 million yuan, 717 million yuan, and 980 million yuan, with a compound annual growth rate of 35.56% [3] - The net profit for the same period is expected to be -602 million yuan, -383 million yuan, and 33.54 million yuan, indicating a turnaround to profitability in 2024 [3] Group 4: IPO and Fundraising - Baiaosaitu plans to raise 1.185 billion yuan through its IPO, which will be directed towards enhancing its existing business and core technologies [3] - The fundraising will support projects aimed at expanding the production capacity of model animals, improving early drug discovery capabilities, and enriching the preclinical research pipeline [3]

建议关注：①全球大单品：百济神州(06160)，科伦博泰生物(06990)，信达生物(01801)，康方生物 (09926)，三生制药(01530)，百利天恒(688506.SH)，新诺威(300765.SZ)，石药集团(01093)，翰森制药 (03692)，中国生物制药(01177)，一品红(300723.SZ)，映恩生物(09606)； ②全球BIC潜力：益方生物(688382.SH)，泽璟制药(688266.SH)，基石药业(01592)，苑东生物 (688513.SH)，科济药业(02171)，来凯医药(02105)，复宏汉霖(02696)，再鼎医药(09688)，和黄医药 (00013)，药捷安康(02617)，加科思(01167)，歌礼制药(01672)； ③国内大单品：舒泰神(300204.SZ)，艾力斯(688578.SH)，云顶新耀(01952)，恒瑞医药(600276.SH)，贝 达药业(300558.SZ)，华领医药(02552)； ④资产价值：和铂医药(02142)，和誉(02256)。 立足现在：进军全球商业化，大量优质项目将继续推高产业发展 中国创新药行业已形成以领头企业为引领、 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) announced a mid-term dividend of HKD 0.2316 per share for the six months ending June 30, 2025, to be distributed on October 30, 2025 [1] Company Summary - The mid-term dividend reflects the company's ongoing commitment to returning value to shareholders [1] - The dividend amount is set at HKD 0.2316 per share, indicating the company's financial health and profitability for the specified period [1]

EF001 | EF001 | | --- | 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 | 為享有股息權利而行使轉換權之最後 | 2025年9月25日 | 16:30 | | --- | --- | --- | | 時限 | | | | 其他信息 | | | | 其他信息 | 不適用 | | | 發行人董事 | | | | | | 於本公告日期，董事會成員包括主席兼執行董事鍾慧娟女士、執行董事孫遠女士及呂愛鋒博士；及獨立非執行董事林國強先生、陳 | 免責聲明 尚偉先生及楊東濤女士。 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 翰森製藥集團有限公司 | | 股份代號 03692 | | | 多櫃檯股份代號及貨幣 不適用 | | | 相關股份代號及名稱 40546 | 600百萬美元於二零二六年到期的零息可換股債券 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 | | 原日期 | 重新編排日期 | | --- | --- | --- | | 為符合獲取股息分派而遞交 | 二零二五年 | 二零二五年 | | 股份過戶文件之最後時限 | 九月二十三日 | 九月二十五日 | | | 下午四時三十分 | 下午四時三十分 | | 暫停辦理股份過戶登記 | 由二零二五年九月二十 | 由二零二五年九月二十 | | 手續之日期 | 四日至二零二五年九月 | 六日至二零二五年九月 | | | 二十五日（包括首尾兩 | 二十九日（包括首尾兩 | | | 天） | 天） | | 記錄日期 | 二零二五年 | 二零二五年 | | | 九月二十五日 | 九月二十九日 | 1 除上文所披露者外，本公司確認中期股息派發日仍為二零二五年十月三十日，而 中期業績公告及中期報告所載之所有 ...

Core Insights - The prevalence of insomnia in China is increasing due to factors such as aging and unhealthy lifestyles, making sleep health a key indicator of the Healthy China strategy [1] - A forum held on September 21 in Beijing highlighted new data, methods, and initiatives for insomnia treatment, aiming to promote national sleep health [1] Group 1: Sleep Health Statistics - According to the China Sleep Research Society's 2025 Sleep Health Survey, 48.5% of individuals aged 18 and above in China experience sleep disturbances, primarily characterized by difficulty falling asleep, nighttime awakenings, and early waking [2] - Long-term insomnia is linked to serious health issues, including hypertension, diabetes, coronary heart disease, cancer, and an increased risk of dementia [2] Group 2: Current Treatment Limitations - Traditional insomnia medications, such as benzodiazepines and non-benzodiazepines, can shorten sleep onset but may lead to daytime drowsiness, cognitive decline, and dependency, posing significant risks for long-term use [2] - There is a lack of safe and effective long-term treatment options for insomnia in China, with existing medications often failing to meet public expectations for quality sleep [2] Group 3: Innovative Treatment Approaches - Dual Orexin Receptor Antagonists (DORAs) have received first-line recommendations in treatment guidelines, marking a significant advancement in insomnia therapy [3] - DORAs work by blocking the binding of orexin neuropeptides to their receptors, effectively lowering orexin levels and promoting natural sleep without the widespread sedation associated with traditional medications [3] Group 4: Clinical Research and Efficacy - DORA medications, such as Daridorexant, have shown consistent efficacy and safety in clinical trials, with patients experiencing a reduction in sleep onset time by 35 minutes and nighttime awakenings by 30 minutes, while extending total sleep time by one hour [4] - Daridorexant has been recognized as a first-line treatment for insomnia in Europe, with clinical studies indicating improved sleep quality without the residual effects commonly seen with traditional medications [4] Group 5: Market Development and Future Research - Companies like Yangtze River Pharmaceutical Group and Hansoh Pharmaceutical are investing in the development of new insomnia medications, with Daridorexant already commercialized in China [5] - A national sleep disorder screening project has been launched to establish a sleep health database and explore new treatment models, with a planned investment of 30 million yuan for post-marketing research on insomnia medications [6]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has finally received the opportunity for its IPO review after over two years of waiting on the Sci-Tech Innovation Board, with the Shanghai Stock Exchange's listing review committee scheduled to meet on September 24, 2025, to discuss the company's initial public offering [1] Company Overview - Established in 2009, Baiaosaitu is a preclinical CRO and biotechnology company that provides various innovative model animals and preclinical drug development services based on its self-developed gene editing technology [1] - The company utilizes its proprietary RenMice fully human antibody mouse platform for large-scale drug discovery and development targeting nearly a thousand potential drug targets, referred to as the "Thousand Mice Ten Thousand Antibodies" initiative [1] IPO Process and Financial Performance - Baiaosaitu was listed on the Hong Kong Stock Exchange under Rule 18A in 2022 and had its Sci-Tech Innovation Board IPO accepted on June 20, 2023, entering the inquiry stage on July 18, 2023, after undergoing two rounds of inquiries [3] - The company reported revenues of approximately 534 million yuan, 717 million yuan, and 980 million yuan for the years 2022 to 2024, with corresponding net profits of approximately -602 million yuan, -383 million yuan, and 33.54 million yuan [4] - In the first half of this year, Baiaosaitu achieved revenue of 621 million yuan, a year-on-year increase of 51.27%, and a net profit of approximately 47.99 million yuan, marking a turnaround from losses [4] Business Model and Collaborations - The "Thousand Mice Ten Thousand Antibodies" initiative has generated significant commercial interest, with the company forming partnerships with numerous well-known pharmaceutical companies, including Merck, Gilead, and Neurocrine, among others [3] - The company has established a stable core management and R&D team, with core business areas showing growth and R&D investments maintained at reasonable levels, indicating an expected gradual enhancement in profitability [5] Fundraising and Strategic Direction - Baiaosaitu has reduced its initial fundraising target from 1.893 billion yuan to 1.185 billion yuan, with the funds aimed at early drug development service platform construction, antibody drug research and evaluation projects, and working capital [5][6] - The company emphasizes that the reduction in fundraising scale will not alter its strategic direction, as core fundraising projects will still focus on its main business and technology platform [6]